Archive — US — techcrunch
Google plans to release new ‘open’ AI models for drug discovery
Google announced plans for TxGemma, a collection of open AI models for drug discovery that will launch through its Health AI Developer Foundations program later this month. These models can analyze text and therapeutic structures to streamline drug development, but commercial usage details remain unclear.
Key points
- Google is developing TxGemma, open AI models aimed at drug discovery.
- These models understand both text and biochemical structures.
- Karen DeSalvo emphasized the need for efficiency in the drug development process.
- TxGemma can help predict properties of new therapies.
- Uncertainty exists around the models' licensing for commercial applications.
- AI's role in drug discovery has seen both promise and challenges.
- Several recent clinical trial failures highlight risks in AI-driven drug development.
- Investor interest remains high, with significant funding in AI drug discovery.
Why it matters
- AI-driven drug discovery reflects a broader trend in healthcare innovation.
- Historical successes and failures highlight the ongoing challenge in pharmaceutical R&D.
- Current enthusiasm in AI technology parallels other tech trends in healthcare, particularly post-COVID.
- In 2025, continued advancements in AI models are expected to reshape the landscape of drug discovery.
Google's TxGemma initiative represents a significant step in leveraging AI for drug discovery, addressing historical inefficiencies, despite past challenges and uncertainties in the field.